#AstraZeneca could be just months away from #FDA approval of a new #bladdercancer indication for its #PDL1inhibitor #Imfinzi, which is viewed as key to meeting its sales ambitions for the drug.
@pharmaphorum.bsky.social
@pharmaphorum.bsky.social#AstraZeneca could be just months away from #FDA approval of a new #bladdercancer indication for its #PDL1inhibitor #Imfinzi, which is viewed as key to meeting its sales ambitions for the drug.
@medchemexpress.bsky.social🚨Phase 3 DeLLphi-305 showed that #tarlatamab-dlle (#IMDELLTRA, Amgen) + #durvalumab (#IMFINZI, AstraZeneca) significantly improved overall survival versus durvalumab alone in the first-line maintenance setting.
@newsen.bsky.socialSignificant Survival Improvement in Extensive Stage Small Cell Lung Cancer with IMDELLTRA and IMFINZI Combination #USA #Thousand_Oaks #SCLC #IMDELLTRA #IMFINZI